Gastroenteritis News and Research RSS Feed - Gastroenteritis News and Research

Gastroenteritis (also known as gastro, gastric flu, and stomach flu) refers to inflammation of the gastrointestinal tract, involving both the stomach and the small intestine and resulting in acute diarrhea. The inflammation is caused most often by infection with certain viruses, less often by bacteria or their toxins, parasites, or adverse reaction to something in the diet or medication.
Novartis gets three FDA approvals for expanded use of biologic drug to treat rare autoinflammatory diseases

Novartis gets three FDA approvals for expanded use of biologic drug to treat rare autoinflammatory diseases

Novartis announced today that the US Food and Drug Administration has granted three simultaneous approvals for the expanded use of Ilaris (canakinumab) to treat three rare and distinct types of Periodic Fever Syndromes. [More]
Scientists grow noroviruses in laboratory cultures of human intestinal epithelial cells

Scientists grow noroviruses in laboratory cultures of human intestinal epithelial cells

Human noroviruses - the leading viral cause of acute diarrhea around the world - have been difficult to study because scientists had not found a way to grow them in the lab. [More]
Study estimates health care costs of gastrointestinal illnesses in Switzerland

Study estimates health care costs of gastrointestinal illnesses in Switzerland

In Switzerland, between 300,000 and 700,000 patients per year visit a doctor due to acute diarrhoea. Until now, the financial burden on the Swiss health care system had been completely unclear. [More]
RedHill Biopharma and IntelGenx announce definitive agreement for commercialization of RIZAPORT™ for migraines with Grupo JUSTE in Spain and additional potential territories

RedHill Biopharma and IntelGenx announce definitive agreement for commercialization of RIZAPORT™ for migraines with Grupo JUSTE in Spain and additional potential territories

RedHill Biopharma Ltd., a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases and cancer, together with IntelGenx Corp., a Canadian drug delivery company focused on oral drug delivery, today announced the signing of an exclusive license agreement with Grupo JUSTE S.A.Q.F (“Grupo JUSTE”), for the commercialization of RIZAPORT™ in Spain, and a right of first refusal for additional territories. RIZAPORT™ is a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines. [More]
Researchers uncover sensing mechanism of food poisoning bacteria found in shellfish

Researchers uncover sensing mechanism of food poisoning bacteria found in shellfish

UT Southwestern Medical Center researchers have uncovered a mechanism that a type of pathogenic bacteria found in shellfish use to sense when they are in the human gut, where they release toxins that cause food poisoning. [More]
Scientists explore effects of physiological fluid shear on dangerous type of Salmonella

Scientists explore effects of physiological fluid shear on dangerous type of Salmonella

Once inside the human body, infectious microbes like Salmonella face a fluid situation. They live in a watery world, surrounded by liquid continually flowing over and abrading their cell surfaces--a property known as fluid shear. [More]
Maternal vaccination against influenza can reduce flu risk in newborns

Maternal vaccination against influenza can reduce flu risk in newborns

Each year, influenza causes between 250,000 and half a million deaths around the world. Pregnant women and young infants have a higher risk of complications related to influenza; these complications can easily lead to death. [More]
Rotavirus vaccine program reduces hospitalization rates by more than 70% in Ontario

Rotavirus vaccine program reduces hospitalization rates by more than 70% in Ontario

Hospitalization for rotavirus infections decreased by > 70% following the introduction of a vaccine program in Ontario, Canada, according to a study published May 11, 2016 in the open-access journal PLOS ONE by Sarah Wilson from Public Health Ontario and the Institute for Clinical Evaluative Sciences, Canada, and colleagues. [More]
Half-strength apple juice followed by preferred fluid choice better for treating kids with mild gastroenteritis

Half-strength apple juice followed by preferred fluid choice better for treating kids with mild gastroenteritis

Children with mild gastroenteritis and minimal dehydration experienced fewer treatment failures such as IV rehydration or hospitalization when offered half-strength apple juice followed by their preferred fluid choice compared with children who received electrolyte maintenance solution to replace fluid losses, according to a study published online by JAMA. The study is being released to coincide with its presentation at the Pediatric Academic Societies meeting. [More]
Research highlights global economic burden of norovirus

Research highlights global economic burden of norovirus

While norovirus is often linked in the news to outbreaks on cruise ships, the highly contagious stomach bug sickens nearly 700 million around the world every year and results in roughly $4.2 billion in health care costs and $60.3 billion in societal costs annually, new Johns Hopkins Bloomberg School of Public Health research suggests. [More]
RedHill Biopharma initiates phase II study of BEKINDA for irritable bowel syndrome

RedHill Biopharma initiates phase II study of BEKINDA for irritable bowel syndrome

RedHill Biopharma Ltd. (NASDAQ; RDHL) (TASE: RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that it has initiated a randomized, double-blind, 2-arm parallel group Phase II clinical study in the U.S. evaluating the safety and efficacy of BEKINDA™ 12 mg in patients with diarrhea-predominant irritable bowel syndrome (IBS-D). [More]
Electronic health records could help identify people who have undiagnosed type 2 diabetes

Electronic health records could help identify people who have undiagnosed type 2 diabetes

In 2012, a group of UCLA researchers set out to mine thousands of electronic health records for a more accurate and less expensive way to identify people who have undiagnosed type 2 diabetes. The researchers got much more than they bargained for. [More]
Co-parenting a child has bigger impact on the immune system than flu vaccine or gastroenteritis

Co-parenting a child has bigger impact on the immune system than flu vaccine or gastroenteritis

Raising a child together has a greater effect on your immune system than the seasonal 'flu vaccine or travellers' gastroenteritis, a study by researchers at VIB and KU Leuven in Belgium and the Babraham Institute in the UK has found. [More]
Immune signaling molecule in infected mothers linked to behavioral abnormalities in offspring

Immune signaling molecule in infected mothers linked to behavioral abnormalities in offspring

In 2010, a large study in Denmark found that women who suffered an infection severe enough to require hospitalization while pregnant were much more likely to have a child with autism (even though the overall risk of delivering a child with autism remained low). [More]
Amgen announces approval of cholesterol-lowering medication Repatha (evolocumab) Injection in Japan

Amgen announces approval of cholesterol-lowering medication Repatha (evolocumab) Injection in Japan

Amgen today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication Repatha (evolocumab) Injection, the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to be approved in Japan. [More]
Treated greywater does not pose risk for water-related diseases

Treated greywater does not pose risk for water-related diseases

Researchers at the Zuckerberg Institute for Water Research at Ben-Gurion University of the Negev have determined that treated greywater is safe for irrigation and does not pose a risk for gastrointestinal illness or water-related diseases. [More]
Frequent infections in early life may increase risk factor for coeliac disease development in later life

Frequent infections in early life may increase risk factor for coeliac disease development in later life

Children with frequent infections in the first 18 months of life have a slightly increased risk of later developing coeliac disease compared with children who have few infections. This is the conclusion from a study by the Norwegian Institute of Public Health. [More]
BD Life Sciences announces FDA clearance for BD MAX Enteric Parasite Panel

BD Life Sciences announces FDA clearance for BD MAX Enteric Parasite Panel

BD Life Sciences, a segment of global medical technology company BD (Becton, Dickinson and Company), today announced the availability of the U.S. Food and Drug Administration cleared BD MAX Enteric Parasite Panel for use on the BD MAX System. [More]
NHS Trust uses clinical measures, computer-based surveillance to reduce norovirus outbreaks by over 90%

NHS Trust uses clinical measures, computer-based surveillance to reduce norovirus outbreaks by over 90%

An NHS Trust has cut outbreaks of the norovirus winter vomiting bug by more than 90% over a five-year period, according to research published in the journal BMJ Quality and Safety. [More]
Study finds significant decline in CT usage at children's hospitals for common childhood diagnoses

Study finds significant decline in CT usage at children's hospitals for common childhood diagnoses

A study published online Aug. 24 by the journal Pediatrics finds a significant decrease in the use of computed tomography (CT) scans at children's hospitals for 10 common childhood diagnoses including seizure, concussion, appendectomy and upper respiratory tract infection. [More]
Advertisement
Advertisement